Compositions and methods for inhibiting expression of 3-hydroxy-3-methylglutaryl-coa reductase (HMGCR)

TW202626068APending Publication Date: 2026-07-01SHANGHAI ARGO BIOPHARMACEUTICAL CO LTD

0 Cites 0 Cited by

Patent Information

Application Number: TW114150052
Authority / Receiving Office: TW · TW
Patent Type: Applications
Current Assignee / Owner
Filing Date: 2025-12-19
Publication Date: 2026-07-01

Application Information

Patent Timeline

19 Dec 2025

Application

TW114150052

01 Jul 2026

Publication

TW202626068A

IPC: A61K31/713; A61P3/06; A61P9/00; C12N15/113

Inventors: 舒東旭; 邵鵬程

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Abstract

Compositions and methods useful to reduce expression of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) gene and for treatment of HMGCR-associated diseases and conditions are provided. Provided are HMGCR dsRNA agents, HMGCR antisense polynucleotide agents, compositions comprising HMGCR dsRNA agents, and compositions comprising HMGCR antisense polynucleotide agents that can be used to reduce HMGCR expression in cells and subjects.

Need to check novelty before this filing date? Find Prior Art